Inhibitors of N-glycosylation as a potential tool for analysis of the mechanism of action and cellular localisation of glycoprotein P

• Autorzy: Wojtowicz K. , Szaflarski W. , Januchowski R. , Zawierucha P. , Nowicki P. , Zabel M.
• Języki publikacji: EN

Abstrakty

EN

 Multidrug resistance has for many years attracted attention of numerous investigators. Attempts have also been made to increase efficiency of anti-neoplastic therapy. For this reason, most of efforts have been devoted to analysing proteins engaged in the mechanism of multidrug resistance such as the N-glycosylated membrane protein glycoprotein P. Interestingly, glycosylation probably plays a significant role in the intracellular location and activity of modified proteins. Inhibitors of glycosylation have been demonstrated to alter the activity of glycoprotein P in various ways, depending on the cell line examined. These inhibitors markedly reduce multidrug resistance of cancer cells, thus promoting success of anti-neoplastic therapy. Here, we review the basic knowledge on N-glycosylation inhibitors, their effect on glycoprotein P and their therapeutic potential.

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2012
• Tom: 59
• Numer: 4
• Opis fizyczny: p.445-450,fig.,ref.

Twórcy

autor

Wojtowicz K.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland

autor

Szaflarski W.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland

autor

Januchowski R.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland

autor

Zawierucha P.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland

autor

Nowicki P.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland

autor

Zabel M.

• Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
• Department of Histology and Embryology, Wroclaw Medical University, Wrocław, Poland

Bibliografia

• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485. 
• Andresen L, Skovbakke SL, Persson G, Hagemann-Jensen M, Hansen KA, Jensen H, Skov S (2012) 2-Deoxy d-glucose prevents cell surface expression of NKG2D ligands through inhibition of n-linked glycosylation. J Immunol 188: 1847-1855. 
• Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A (2006) Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. World J Gastroenterol 12: 3636-3644. 
• Bentley J, Quinn DM, Pitman RS, Warr JR, Kellett GL (1997) The human KB multidrug-resistant cell line KB-Cl is hypersensitive to inhibitors of glycosylation. Cancer Lett 115: 221-227. 
• Brasse-Lagnel C, Fairand A, Lavoinne A, Husson A (2003) Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic O-glycosylation of Sp1 in Caco-2 Cells. J Biol Chem 278: 52504-52510. 
• Buscà PR, Pujana MA, Pognonec P, Auwerx J, Deeb SS, Reina M, Vilaró S (1995) Absence of N-glycosylation at asparagine 43 in human lipoprotein lipase induces its accumulation in the rough endoplasmic reticulum and alters this cellular compartment. J Lipid Res 36: 939-951. 
• Carver JP, Dennis JW (1995) Inhibitors of carbohydrate processing: a new class of anticancer agents. Clin Cancer Res 1: 935-944. 
• Chen K, Valencia J, Gillet J, Hearing V, Gottesman M (2009) Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res 22: 740-749. 
• Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS (2010) Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res 16: 3205-3214. 
• Datta U, Dasgupta A (1994) Expression and subcellular localization of poliovirus VPg-precursor protein 3AB in eukaryotic cells: evidence for glycosylation in vitro. J Virol 68: 4468-4477. 
• de Freitas Junior JC, D'Aguiar Silva BD, de Souza WF, de Araújo WM, Abdelhay ES, Morgado-Díaz JA (2011) Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell-cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells. Cancer Chemother Pharmacol 68: 227-238. 
• Delom F, Emadali A, Cocolakis E, Lebrun JJ, Nantel A, Chevet E (2007) Calnexin-dependent regulation of tunicamycin induced apoptosis in breast carcinoma MCF-7 cells. Cell Death Differ 14: 586-596. 
• Delou JM, Lopes AG, Capella MA (2009) Unveiling the role of multidrug resistance proteins in hypertension. Hypertension 54: 210-216. 
• Dennis JW, Granovsky M, Warren CE (1999) Protein glycosylation in development and disease. BioEssays 21: 412-421. 
• Draheim V, Reichel A, Weitschies W, Moenning U (2010) N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci 41: 201-209. 
• Dricu A, Carlberg M, Wang M, Larsson O (1997) Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res 57: 543-548. 
• Dwarakanath BS (2009) Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro. J Cancer Res Ther 5: S27-S31. 
• Elbein AD (1991) Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J 5: 3055-3063. 
• Fu D, Arias IM (2012) Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol 44: 461-464. 
• Gaddameedhi S, Chatterjee S (2009) Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics. J Cancer Res Ther 5: S61-S66. 
• Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76. 
• Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV (2000) Functional characterization of glycosylation-deficient human p-glycoprotein using a vaccinia virus expression system. J Membr Biol 173: 203-214. 
• Grosso FD, Mariano MD, Passoni L, Luksch R, Tonini GP, Longo L (2011) Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines. BMC Cancer 11: 525. 
• Hiss DC, Gabriels GA, Folb PI (2007) Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int 7: 5. 
• Jacob GS (1995) Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol 5: 605-611. 
• Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162. 
• Klausner RD, Donaldson JG, Lippincott-Schwartz J (1992) Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 116: 1071-1080. 
• Kramer R, Weber TK, Morse B, Arceci R, Staniunas R (1993) Constitutive expression of multidrug resistance in human colorectal tumors and cell lines. Br J Cancer 67: 959-968. 
• Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis MV, Steele G Jr, Summerhayes IC (1995) Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 71: 670-675. 
• Ledoux S, Yang R, Friedlander G, Laouari D (2003) Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 63: 7284-7290. 
• Liu YY, Han TY, Giuliano AE, Cabot MC (2001) Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730. 
• Loo TW, Clarke DM (1998) Quality control by proteases in the endoplasmic reticulum. Removal of a protease-sensitive site enhances expression of human P-glycoprotein. J Biol Chem 273: 32373-32376. 
• Loo TW, Clarke DM (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 13: 1724-1732. 
• Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA, Redfern CP (2008) Increasing melanoma cell death using inhibitors of protein disulphide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 68: 5363-5369. 
• Lugemwa FN, Sarkar AK, Esko JD (1996) Unusual β-D-xylosides that prime glycosaminoglycans in animal cells. J Biol Chem 271: 19159-19165. 
• Marchal I, Mir AM, Kmiécik D, Verbert A, Cacan R (1999) Use of inhibitors to characterize intermediates in the processing of N-glycans synthesized by insect cells: a metabolic study with Sf9 cell Line. Glycobiology 9: 645-654. 
• Marchetti S, Mazzanti R, Beijnen J, Schellens J (2007) Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 12: 927-941. 
• Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, Toccacieli L, Marra M, Colone M, Cianfriglia M, Arancia G (2002) Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 3: 653-670. 
• Nakajima M, Koga T, Sakai H, Yamanaka H, Fujiwara R, Yokoi T (2010) N-Glycosylation plays a role in protein folding of human UGT1A9. Biochem Pharmacol 79: 1165-1172. 
• Nebenfuhr A, Ritzenthaler C, Robinson DG (2002) Brefeldin A: Deciphering an Enigmatic Inhibitor of Secretion. Plant Physiology 130: 1102-1108. 
• Noda I, Fujieda S, Seki M, Tanaka N, Sunaga H, Ohtsubo T, Tsuzuki H, Fan GK, Saito H (1999) Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells. Int J Cancer 80: 279-284. 
• Ohtsubo K, Marth JD (2006) Glycosylation in Cellular Mechanisms of Health and Disease. Cell 126: 855-867. 
• Potter-Perigo S, Braun KR, Schönherr E (1991) Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from β-d-xyloside inhibition of proliferation. Arch Biochem Biophys 297: 101-109. 
• Sarkadi B, Homolya L, Szakàcs G, Vàradi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236. 
• Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E (1992) N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268: 7474-7481. 
• Schwarz F, Aebi M (2011) Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol 21: 576-582. 
• Šereš M, Cholujová D, Bubenčíkova T, Breier A, Sulová Z (2011) Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 Cells. Int J Mol Sci 12: 7772-7784. 
• Sorokin D, Duś D (1999) Role of P-gp and other transport proteins in multidrug resistance. Nowotwory 49: 573-581 (in Polish).
• Straumann N, Wind A, Leuenberger T, Wallimann T (2006) Effects of N-linked glycosylation on the creatine transporter. Biochem J 393: 459-469. 
• Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA (2006) A comparison of the β-d-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost 4: 1989-1996. 
• Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, eds (2009) Essentials of Glycobiology. 2nd edn. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press. 
• Walsh MT, Foley JF, Kinsella BT (1998) Characterization of the role of N-linked glycosylation on the cell signaling and expression of the human thromboxane A2 Receptor Alpha and Beta Isoforms. J Pharmacol Exp Ther 286: 1026-1036. 
• Wu F, Lukinius A, Bergström M, Eriksson B, Watanabe Y, Längström B (1999) A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria. Eur J Cancer 35: 1155-1161. 
• Zhang Z, Wu JY, Hait WN, Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66: 395-403. 
• Zhao Y, Zhou Y, O' Boyle KM, Murphy PV (2010) Biological study of the angiogenesis inhibitor N-(8-(3-ethynylphenoxy)octyl-1-deoxynojirimycin. Chem Biol Drug Des 75: 570-577. 
• Zhou F, Xu W, Hong M, Pan Z, Sinko PJ, Ma J, You G (2005) The role of N-linked glycosylation in protein folding, membrane targeting, and substrate binding of human organic anion transporter hOAT4. Mol Pharmacol 67: 868-876. 

Uwagi

rekord w opracowaniu